NICE recommends use of cabazitaxel in combination with prednisone or prednisolone only if:
• the person has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1• the person has had 225 mg/m2 or more of docetaxel
• treatment with cabazitaxel is stopped when the disease progresses or after a maximum of 10 cycles (whichever happens first)
• NHS trusts purchase cabazitaxel in pre‑prepared intravenous‑infusion bags, not in vials, and• the company provides cabazitaxel with the discount agreed in the patient access scheme.